KaydedilenlerDerginizi ekleyin

Dergiler / Infectious diseases and clinical microbiology (Online) / 2022 / Cilt: 4 - Sayı: 2

Management of COVID-19 Cases in Kosova

Lindita Ajazaj BERİSHA
Salih AHMETİ
Sadije Namani AVDİU
Arben VISHAJ
Izet SADIK
Şiran KESKE
Faik HOTI
Hysen AHMETİ
Nahit ÇAKAR
Bilgin SAIT
Mentor ALIMUSAJ
Önder ERGÖNÜL
Sayfa
144–147
Yayın Tarihi
2022-10-19
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
🔖

Bu Makaleye Atıf Yap

BERİSHA, L. A., AHMETİ, S., AVDİU, S. N., VISHAJ, A., SADIK, I., KESKE, Ş., HOTI, F., AHMETİ, H., ÇAKAR, N., SAIT, B., ALIMUSAJ, M., ERGÖNÜL, Ö. (2022). Management of COVID-19 Cases in Kosova. Infectious diseases and clinical microbiology (Online), Cilt: 4 - Sayı: 2, 144–147. https://ajindex.com/articles/539055

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (10)

  1. 1 Therapeutics and COVID-19: Living Guideline, 2020 [Internet]. Geneva: World Health Organization. (cited February 8, 2022). Available from: https://app.magicapp.org/#/guideline/nBkO1E/ section/j197zj 2 Özlüşen B, Kozan Ş, Akcan RE, Kalender M, Yaprak D, Peltek IB, et al. Effectiveness of favipiravir in COVID-19: a live systematic review. Eur J Clin Microbiol Infect Dis. 2021
  2. 40(12):2575-83. [CrossRef] 3 Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID COVID-19 living guidelines: drug treatment and clinical management. Clin Microbiol Infect. 2022
  3. 28(2):222-38. [CrossRef] 4 Yamakawa K, Yamamoto R, Terayama T, Hashimoto H, Ishihara T, Ishimaru G, et al
  4. Special Committee of the Japanese Clinical Practice Guidelines for the Management of Sepsis and Septic Shock 2020 (J-SSCG 2020), the COVID-19 Task Force. Japanese rapid/living recommendations on drug management for COVID-19: updated guidelines (September 2021). Acute Med Surg. 2021
  5. 8(1):e706. [CrossRef] 5 Bhimraj A, Morgan RL, Hirsch-Shumaker A, Lavergne V, Baden L, Cheng CV, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19 [Internet]. Arlington: Infectious Diseases Society of America (IDSA). (updated May 10, 2022
  6. cited February 8, 2022). Available from: https://www.idsociety. org/practice-guideline/covid-19-guideline-treatmentand- management/ 6 Therapeutics and COVID-19: Living Guideline, 2022 [Internet]. Geneva: World Health Organization. (cited February 8, 2022). Available from: https://www.who.int/publications/i/item/ WHO-2019-nCoV-therapeutics-2022.3 7 Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022
  7. 386(6):509-20. [CrossRef] 8 Dyer O. Covid-19: FDA expert panel recommends authorising molnupiravir but also voices concerns. BMJ. 2021
  8. n2984. [CrossRef] 9 Mahase E. Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports. BMJ. 2021
  9. n2713. [CrossRef] 10 Therapeutics and COVID-19: Living Guideline, 2021 [Internet]. Geneva: World Health Organization. (cited February 8, 2022). Available from: https://app.magicapp.org/#/guideline/nBkO1E/ rec/jOp0R7 11 RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021
  10. 384 (8):693-704. [CrossRef] 12 RECOVERY Collaborative Group